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Interstitial lung disease (ILD) is a slowly pro-
gressive inflammatory disease that is associated 
with a poor prognosis because it frequently induc-
es life-threatening complications such as respira-
tory and heart failure.  Estimates indicate that 
many patients with esophageal cancer would de-
velop comorbid ILD because esophageal squamous 
cell carcinoma and several types of ILD are closely 
associated with smoking.  However, treatment for 
esophageal cancer with ILD has not been de-
scribed in the literature and selecting the optimal 
treatment for such patients can be a source of con-
siderable anguish because clear treatment guide-
lines are unavailable.  Here, we describe a patient 
with esophageal cancer complicated with ILD that 
was successfully treated by surgery.  To our 
knowledge, this is the first report of surgical treat-
ment for esophageal cancer with ILD.
CASE REPORT
Gastrointestinal fiberscopy of a 72-year-old man 
who was referred to our institution revealed multi-
ple esophageal tumors.  Endoscopic ultrasound in-
dicated that a mid-thoracic tumor extending over 
two-thirds of the esophageal circumference had in-
vaded the submucosal layer and the pathological 
diagnosis of biopsy specimens was moderately dif-
ferentiated squamous cell carcinoma (Fig. 1).  The 
other three esophageal tumors were thought to be 
mucosal cancers.  Computed tomography (CT) did 
not show either enlarged lymph nodes or distant 
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Fig. 1. Gastrointestinal fiberscopy of esophageal cancer.
Tumor located 28 cm from incisors has extended over 
two-thirds of esophageal circumference. Submucosal 
invasion was suspected.
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prednisolone (10 mg/day).  He had a smoking his-
tory of > 50 years, and stopped smoking upon re-
ceiving this diagnosis.  The symptoms had almost 
completely disappeared and the KL-6 level had be-
come normalized within six months, so the steroid 
medication was stopped at that time.
The KL-6 level was within the normal range, and 
the bilateral ground-glass and reticular opacities on 
CT images had improved but were still evident when 
the patient was diagnosed with esophageal cancer 
(Fig. 2B).  His pulmonary function was within the 
normal value for %vital capacity (117%) and forced 
expiratory volume per 1s% (70.6%).  However, the 
%diffusing capacity for carbon monoxide was very 
low (43.0%).
The esophageal cancers were multiple, and four 
lesions existed throughout thoracic esophagus. 
Furthermore, the mid-thoracic esophageal cancer 
occupied over two-thirds of the circumference and 
was thought to have invaded the deep submucosal 
layer.  Overall, these esophageal cancers were not 
considered an indication for endoscopic resection in 
metastasis.  F-18-fluorodeoxyglucose positron emis-
sion tomography/computed tomography (FDG-PET/
CT) revealed abnormal tracer accumulation only in 
the mid-thoracic esophageal tumor with a maxi-
mum standard uptake value of 3.3.  The levels of 
tumor markers such as squamous cell carcinoma 
(SCC)-related antigen were all within normal 
ranges.  Based on these findings, stage IA esopha-
geal cancer was clinically diagnosed according to 
the TNM Classification of Malignant Tumors 7th 
edition19).
A medical history of ILD affected the treatment 
choice.  The patient had attended a hospital with 
dyspnea upon physical exertion 18 months before 
esophageal cancer was identified.  Chest X-ray and 
CT images revealed emphysema of the apex area 
and bilateral ground-glass and reticular opacities 
(Fig. 2A).  Bronchoscopy revealed lymphocytosis 
in bronchoalveolar lavage fluid and blood chemis-
try findings showed significantly elevated levels of 
KL-6 (1030 U/mL).  He was diagnosed with active 
interstitial lung disease, and was prescribed with 
Fig. 2. Chest CT images.
(A) Bilateral ground-glass and reticular opacities 18 months before esophageal tumors were identified.
(B) Bilateral ground-glass and reticular opacities have improved but remain extant at the time of surgery.
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have investigated the surgical outcomes of lung 
cancer3,9,11,22) or lung biopsies for ILD patients10,18). 
Reports indicate that ILD is a risk factor for devel-
oping postoperative morbidity, mortality and poor 
long-term survival.  In particular, 13.5 - 25.0% of 
patients with lung cancer experienced acute exacer-
bation of ILD, and it induced acute lung injury and 
is often fatal.  Postoperative mortality rate was re-
portedly 2.8% - 16.6%3,9,22).
To our knowledge, the incidence of respiratory 
complications after resection of esophageal cancer 
with ILD has not been described.  However, pa-
tients with esophageal cancer even without ILD 
often develop respiratory complications that some-
times induce acute lung injury12,20).  Tandon et al 
investigated risk factors for acute lung injury after 
surgery for esophageal cancer.  They reported that 
obesity, a history of smoking, the experience of the 
surgeon, the duration of both the operative proce-
dure and of one-lung ventilation and the occur-
rence of postoperative anastomotic leak are risk 
factors for acute lung injury20).  Surgical stress is 
generally considered to be associated with postop-
erative respiratory complications12).
Indeed, several investigators have examined the 
application of drugs to suppress surgical stress. 
Administering corticosteroids before esophagecto-
my helps to prevent postoperative acute lung injury 
and respiratory failure15,17).  The selective inhibitor 
of neutrophil elastase, sivelestat, should also help 
to reduce postoperative acute lung injury14).  The 
perioperative administration of sivelestat helps to 
reduce postoperative hypoxia, suppresses postoper-
ative hypercytokinemia, shortens the duration of 
systemic inflammatory response syndrome and im-
proves postoperative respiratory function8,13).  We 
routinely administer corticosteroids before starting 
esophagectomy and perioperatively administer sive-
lestat for patients at high risk of respiratory compli-
cations.
The surgical procedure is also important to reduce 
surgical stress.  Transthoracic esophagectomy (TTE) 
with systematic lymphadenectomy is a standard pro-
cedure for treating thoracic esophageal cancer.  On 
the other hand, THE, which comprises cervical and 
abdominal approaches, is thought to be limited by 
the impossibility of systematic mediastinal lymph-
adectomy7).  Transhiatal esophagectomy is some-
times adopted to decrease postoperative risk because 
thoracotomy is not required.  A meta-analysis of 
THE compared with TTE associated the former with 
a shorter surgical duration, significantly less respi-
ratory complications and early postoperative mortal-
ity.  Others have associated THE with a significantly 
shorter hospital stay2,4).
Our patient had esophageal cancer with suspected 
deep submucosal layer invasion, but without evident 
lymph node metastasis upon clinical evaluation. 
However, he was considered to be at high risk for 
postoperative respiratory complications due to hav-
view of curability and feasibility by a gastroenter-
ologist.  The radiologist also judged that radiother-
apy would be incompatible because even minimal 
irradiation of the pulmonary parenchyma would 
exacerbate ILD.
We wavered in treatment choice, but it seemed 
that we had no other treatment choice but surgical 
resection.  Therefore, we obtained the patient's in-
formed consent after detailed explanation of the 
advantages and disadvantages of surgical therapy, 
and planned to surgically resect the esophageal 
tumors.  We considered that a procedure via tho-
racotomy and one-lung ventilation would be very 
challenging for this patient, due to a high risk of 
postoperative respiratory complications such as 
ILD acute exacerbation.  Therefore, he was treated 
with transhiatal esophagectomy (THE) without a 
thoracotomy.  The operative duration was 210 min, 
and 130 g of blood was lost.  The patient was ad-
ministered with methylprednisolone (250 mg/
body) at the start of surgery and sivelestat (300 
mg/day) was administered from immediately after 
surgery until postoperative day (POD) 7.  The 
postoperative course was good, and he was dis-
charged on POD 25 without postoperative compli-
cations.  Histopathological assessment showed 
that the esophageal tumor had slightly invaded 
the lymphatic vessels to the depth of the muscula-
ris mucosa.
The metastasis of the left supraclavicular lymph 
nodes developed 5 months after esophagectomy, 
and we performed lymph node dissection followed 
by chemoradiotherapy.  Thereafter, the patient 
was followed-up without treatment by another hos-
pital.  Although the patient died of bone metasta-
sis at 3 years after the first operation, he resumed 
normal activities at home without exacerbation of 
ILD until then.
DISCUSSION
Interstitial lung disease is a heterogeneous entity 
with various clinical presentations.  Several types 
of ILD such as idiopathic pulmonary fibrosis, respi-
ratory bronchiolitis-associated interstitial lung dis-
ease, and desquamative interstitial pneumonia are 
associated with smoking1).  A clinical evaluation of 
our patient could not result in a definite diagnosis. 
Smoking-related ILD was initially suspected be-
cause he was a heavy smoker and CT imaging had 
revealed emphysema.  ILD is associated with a 
high risk of lung cancer5,16), however the relation-
ship between ILD and esophageal cancer is unclear. 
Esophageal cancer combined with ILD poses a 
challenge in terms of cancer treatment, because 
therapeutic choices are limited.  Radiation therapy 
is generally contraindicated for such patients, be-
cause it often acutely exacerbates ILD6,21).  Several 
authors have also stated that thoracic surgery in-
creases risk for patients with ILD.  Some studies 
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Clinical examination of acute exacerbation of 
idiopathic interstitial pneumonia (IIP) combined with 
lung cancer after anti-cancer treatment. Jpn. J. Lung 
Cancer 41: 281-286.
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Hihara, J., Yamashita, Y., et al. 1998. Clinical re-
sults of transhiatal esophagectomy for carcinoma of 
the lower thoracic esophagus according to biological 
markers. Dis. Esophagus 11: 221-225.
8. Kawahara, Y., Ninomiya, I., Fujimura, T., Funaki, 
H., Nakagawara, H., Takamura, H., et al. 2010. 
Prospective randomized controlled study on the effects 
of perioperative administration of a neutrophil elas-
tase inhibitor to patients undergoing video-assisted 
thoracoscopic surgery for thoracic esophageal cancer. 
Dis. Esophagus 23: 329-339.
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fluid. Dis. Esophagus 21: 30-36.
13. Nagai, Y., Watanabe, M., Baba, Y., Iwatsuki, M., 
Hirashima, K., Karashima, R., et al. 2013. Preven-
tive effect of sivelestat on postoperative respiratory 
disorders after thoracic esophagectomy. Surg. Today 
43: 361-366.
14. Ono, S., Tsujimoto, H., Hiraki, S., Takahata, R., 
Kimura, A., Kinoshita, M., et al. 2007. Effects of 
neutrophil elastase inhibitor on progression of acute 
lung injury following esophagectomy. World J. Surg. 
31: 1996-2001.
15. Park, S.Y., Lee, H.S., Jang, H.J., Joo, J. and Zo, J.I. 
2012. Efficacy of intraoperative, single-bolus 
corticosteroid administration to prevent postoperative 
acute respiratory failure after oesophageal cancer 
surgery. Interact. Cardiovasc. Thorac. Surg. 15: 639-
643.
16. Samet, J.M. 2000. Does idiopathic pulmonary fibrosis 
increase lung cancer risk? Am. J. Respir. Crit. Care 
Med. 161: 1-2.
17. Sato, N., Koeda, K., Ikeda, K., Kimura, Y., Aoki, 
K., Iwaya, T., et al. 2002. Randomized study of the 
benefits of preoperative corticosteroid administration 
on the postoperative morbidity and cytokine response 
in patients undergoing surgery for esophageal cancer. 
Ann. Surg. 236: 184-190.
18. Sigurdsson, M.I., Isaksson, H.J., Gudmundsson, 
G. and Gudbjartsson, T. 2009. Diagnostic surgical 
lung biopsies for suspected interstitial lung diseases: 
a retrospective study. Ann. Thorac. Surg. 88: 227-
ing a history of corticosteroid-treated ILD and 
heavy smoking.  Surgery with mediastinal lymphad-
enectomy via thoracotomy and one-lung ventilation 
for this patient was considered too invasive and 
likely to increase the risk of fatal adverse effects. 
Therefore, we prioritized the risk aversion of postop-
erative respiratory complications, and selected THE. 
The patient recovered safely without postoperative 
respiratory complications.
CONCLUSION
The optimal treatment for esophageal cancer 
with ILD is very difficult to determine.  It needs 
more cases to establish a clear treatment choice. 
We selected surgical resection via a transhiatal ap-
proach with administration of methylprednisolone 
and sivelestat for the reduction of surgical stress, 
and the postoperative outcome was excellent. 
Therefore, THE is a useful option for patients with 
early-stage esophageal cancer without lymph node 
metastasis who are at high risk of postoperative 
respiratory complications.  Appropriate treatment 
for esophageal cancer with respiratory comorbidi-
ties should be tailored to individual patients based 
on their current physical status and degree of dis-
ease progression.
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